Sarepta shares briefly leap 80% after FDA approves drug
September 19, 2016 at 10:29 AM EDT
Shares of Sarepta Therapeutics briefly surged more than 80 percent after the FDA approved its muscular dystrophy drug eteplirsen.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.